GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (OTCPK:AMEUF) » Definitions » EV-to-Revenue

AMEUF (Anteris Technologies) EV-to-Revenue : 51.09 (As of May. 13, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Anteris Technologies EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Anteris Technologies's enterprise value is $138.09 Mil. Anteris Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $2.70 Mil. Therefore, Anteris Technologies's EV-to-Revenue for today is 51.09.

The historical rank and industry rank for Anteris Technologies's EV-to-Revenue or its related term are showing as below:

AMEUF' s EV-to-Revenue Range Over the Past 10 Years
Min: -3.85   Med: 4.84   Max: 80.94
Current: 36.51

During the past 13 years, the highest EV-to-Revenue of Anteris Technologies was 80.94. The lowest was -3.85. And the median was 4.84.

AMEUF's EV-to-Revenue is ranked worse than
93.77% of 818 companies
in the Medical Devices & Instruments industry
Industry Median: 3.09 vs AMEUF: 36.51

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-13), Anteris Technologies's stock price is $5.70. Anteris Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.14. Therefore, Anteris Technologies's PS Ratio for today is 39.58.


Anteris Technologies EV-to-Revenue Historical Data

The historical data trend for Anteris Technologies's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anteris Technologies EV-to-Revenue Chart

Anteris Technologies Annual Data
Trend Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.41 16.21 63.99 74.67 44.06

Anteris Technologies Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.99 - 74.67 - 44.06

Competitive Comparison of Anteris Technologies's EV-to-Revenue

For the Medical Devices subindustry, Anteris Technologies's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anteris Technologies's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Anteris Technologies's EV-to-Revenue falls into.


;
;

Anteris Technologies EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Anteris Technologies's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=138.088/2.703
=51.09

Anteris Technologies's current Enterprise Value is $138.09 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anteris Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $2.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anteris Technologies  (OTCPK:AMEUF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Anteris Technologies's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=5.70/0.144
=39.58

Anteris Technologies's share price for today is $5.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was $0.14.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anteris Technologies EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Anteris Technologies's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Anteris Technologies Business Description

Traded in Other Exchanges
Address
9 Sherwood Road, Level 3, Suite 302, Toowong, QLD, AUS, 4066
Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.